Genexine Inc - Asset Resilience Ratio

Latest as of September 2025: 3.45%

Genexine Inc (095700) has an Asset Resilience Ratio of 3.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩12.65 Billion

≈ $8.57 Million USD Cash + Short-term Investments

Total Assets

₩366.23 Billion

≈ $248.19 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2024)

This chart shows how Genexine Inc's Asset Resilience Ratio has changed over time. Check 095700 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Genexine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genexine Inc stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩12.65 Billion	3.45%
Total Liquid Assets	₩12.65 Billion	3.45%

Asset Resilience Insights

Limited Liquidity: Genexine Inc maintains only 3.45% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Genexine Inc Industry Peers by Asset Resilience Ratio

Compare Genexine Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
ALTEOGEN Inc KQ:196170	Biotechnology	55.57%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	34.94%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Inventiva S.A PA:IVA	Biotechnology	52.73%

Annual Asset Resilience Ratio for Genexine Inc (2009–2024)

The table below shows the annual Asset Resilience Ratio data for Genexine Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.30%	₩32.08 Billion ≈ $21.74 Million	₩345.04 Billion ≈ $233.83 Million	-7.83pp
2023-12-31	17.12%	₩64.48 Billion ≈ $43.70 Million	₩376.59 Billion ≈ $255.21 Million	+11.48pp
2022-12-31	5.64%	₩21.94 Billion ≈ $14.87 Million	₩388.78 Billion ≈ $263.47 Million	+1.28pp
2021-12-31	4.36%	₩27.80 Billion ≈ $18.84 Million	₩636.86 Billion ≈ $431.59 Million	+3.24pp
2020-12-31	1.12%	₩6.71 Billion ≈ $4.55 Million	₩596.91 Billion ≈ $404.52 Million	-21.91pp
2019-12-31	23.04%	₩82.52 Billion ≈ $55.92 Million	₩358.18 Billion ≈ $242.73 Million	-7.37pp
2018-12-31	30.41%	₩113.97 Billion ≈ $77.24 Million	₩374.81 Billion ≈ $254.00 Million	+31.37pp
2017-12-31	-0.96%	₩-1.35 Billion ≈ $-917.17K	₩140.73 Billion ≈ $95.37 Million	-18.49pp
2016-12-31	17.52%	₩34.82 Billion ≈ $23.60 Million	₩198.71 Billion ≈ $134.66 Million	-7.73pp
2012-12-31	25.25%	₩16.00 Billion ≈ $10.85 Million	₩63.38 Billion ≈ $42.95 Million	+5.18pp
2011-12-31	20.07%	₩7.86 Billion ≈ $5.33 Million	₩39.19 Billion ≈ $26.56 Million	-17.18pp
2010-12-31	37.25%	₩14.03 Billion ≈ $9.51 Million	₩37.67 Billion ≈ $25.53 Million	-17.50pp
2009-12-31	54.75%	₩23.42 Billion ≈ $15.87 Million	₩42.78 Billion ≈ $28.99 Million	--

pp = percentage points

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$75.97 Million

₩112.11 Billion KRW

Market Cap Rank

#20194 Global

#1039 in Korea

Share Price

₩2465.00

Change (1 day)

+5.34%

52-Week Range

₩2195.00 - ₩7100.00

All Time High

₩131402.78